1-氨基-2,3-二氢-1H-茚-1,5-二羧酸 | 168560-79-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-氨基-2,3-二氢-1H-茚-1,5-二羧酸
• 英文名称: 1-aminoindan-1,5-dicarboxylic acid
• 英文别名: AIDA；(RS)-1-aminoindan-1,5-dicarboxylic acid；UPF 523；1-amino-2,3-dihydroindene-1,5-dicarboxylic acid
• CAS: 168560-79-0
• 化学式: C₁₁H₁₁NO₄
• mdl: MFCD00672638
• 分子量: 221.213
• InChiKey: LSTPKMWNRWCNLS-UHFFFAOYSA-N

物化性质

• 沸点：
  362.26°C (rough estimate)
• 密度：
  1.2818 (rough estimate)
• 溶解度：
  二甲基亚砜：2 毫克/毫升
• 稳定性/保质期：

  避氧化剂

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2922499990

反应信息

• 作为产物：
  描述：

  methyl 5-indanecarboxylate 在 chromium(VI) oxide 、 barium dihydroxide 、 水 、 碳酸氢铵 、 溶剂黄146 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 1-氨基-2,3-二氢-1H-茚-1,5-二羧酸
  参考文献：
  名称：

  1-氨基茚满-1,5-二羧酸：磷脂酶C连锁的代谢型谷氨酸受体的新型拮抗剂。

  摘要：

  DOI：

  10.1021/jm00019a002

文献信息

• Aminomethyl-substituted thiazolobenzimidazole derivative
  申请人：Itahana Hirotsune

  公开号：US20050148642A1

  公开（公告）日：2005-07-07

  This invention relates to the provision of novel aminomethyl-substituted thiazolobenzimidazole derivatives represented by the following general formula (I) or a salt thereof. The aforementioned derivative or a salt thereof has a metabotropic glutamate receptor action and excellent oral activity and is therefore useful as a medicament. (In the formula, R 1 : an oxygen-containing saturated hetero ring or the like, Alk 1 : a lower alkylene, m: 0 or 1, Alk 2 : a lower alkylene which may be substituted with oxo group, n: 0 or 1, X: a bond, O, S or NR 5 , R 3 : H or the like, and R 2 , R 4 , R 5 , R 6 and R 7 : the same or different from one another and each represents H or the like. Provided that R 3 does not represent a lower alkyl or a halogeno-lower alkyl when X is a bond and n is 1. Also, R 4 represents a group other than Me when m is 1, R 1 is OH or OMe and Alk 1 is a C 1-3 alkylene, and further 1) when X is a bond, n is 1 and R 3 is H, or 2) when X is a bond, n is 0 and R 3 is cyclohexane.)

  本发明涉及提供以下一般式（I）或其盐所表示的新型氨甲基取代噻唑苯并咪唑衍生物。上述衍生物或其盐具有代谢型谷氨酸受体作用和良好的口服活性，因此可用作药物。其中，R1：含氧饱和杂环或类似物，Alk1：较低的烷基，m：0或1，Alk2：较低的烷基，可以用氧代基取代，n：0或1，X：键，O，S或NR5，R3：H或类似物，R2，R4，R5，R6和R7：相同或不同，每个代表H或类似物。前提是当X是键且n为1时，R3不代表较低的烷基或卤代较低的烷基。此外，当m为1时，R4代表除Me以外的基团，R1为OH或OMe，Alk1为C1-3烷基，进一步1）当X是键，n为1且R3为H时，或2）当X是键，n为0且R3为环己烷时。
• 1,4-Substituted Piperazine Derivatives
  申请人：Kawamoto Hiroshi

  公开号：US20090062293A1

  公开（公告）日：2009-03-05

  A compound represented by the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 represents a branched lower alkyl group having from 3 to 9 carbon atoms or the like; R 2 represents a 6-membered heteroaryl group having 1 or 2 nitrogen atoms or the like; R 3 represents a hydrogen atom, an alkanoylamino group or the like; R 4 represents a hydrogen atom, a lower alkyl group or the like; X 1 represents an oxygen atom or a sulfur atom; X 2 represents an oxygen atom or a single bond; and m indicates an integer of from 0 to 4. This compound has a metabotropic glutamate receptor 1 inhibitory effect, and therefore is useful for the treatment of a brain disorder such as convulsion, acute pain, inflammatory pain, chronic pain, cerebral infraction or transient cerebral ischemic attack, a mental dysfunction such as schizophrenia, and a disease such as anxiety and drug addition.

  化合物的化学式为（I）或其药学上可接受的盐，其中：R1代表分支的低碳原子数为3至9的烷基或类似物；R2代表含有1或2个氮原子的6元杂环芳基或类似物；R3代表氢原子，烷酰胺基或类似物；R4代表氢原子，低碳原子数的烷基或类似物；X1代表氧原子或硫原子；X2代表氧原子或单键；m表示0至4的整数。该化合物具有代谢型谷氨酸受体1的抑制作用，因此可用于治疗脑部疾病，如惊厥、急性疼痛、炎性疼痛、慢性疼痛、脑梗塞或短暂性脑缺血发作、精神障碍如精神分裂症以及焦虑和药物成瘾等疾病。
• Biaryl derivatives
  申请人：Kawamoto Hiroshi

  公开号：US20070191389A1

  公开（公告）日：2007-08-16

  The present invention relates to a compound represented by the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R 1 is a linear or branched alkoxy group, a cycloalkoxy group, a linear or branched lower alkyl group, etc.; R 2 is halogen atom, a lower alkyl group, etc.; Q 1 is carbon atom or nitrogen atom; Q 2 is carbon atom which may be substituted with oxo group; the formula (III): (II) is a single bond or a double bond; A is a group selected from the group consisting of the substitutent group α; and R 5 is hydrogen atom, a lower alkyl group, cyano group, an alkoxy group or a trialkylsilyl group; having an mGluR1 inhibiting action and being useful as treatment and/or prevention of convulsion, acute pain, cerebral disturbance such as cerebral infarction or transient cerebral ischemia onset, anxiety, chemical dependency or Parkinson's disease.

  本发明涉及一种由以下式（I）表示的化合物或其药学上可接受的盐，其中： R1是线性或支链烷氧基，环烷氧基，线性或支链低烷基等； R2是卤素原子，低烷基等； Q1是碳原子或氮原子； Q2是可能被氧代基取代的碳原子； 式（III）： （II）是单键或双键； A是从取代基α组成的组中选择的一组；以及 R5是氢原子，低烷基，氰基，烷氧基或三烷基硅基； 具有mGluR1抑制作用，可用于治疗和/或预防抽搐，急性疼痛，脑功能障碍，如脑梗死或短暂性脑缺血发作，焦虑，化学依赖或帕金森病。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
  申请人：Vollrath Benedikt

  公开号：US20120270866A1

  公开（公告）日：2012-10-25

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.

  本文提供了PAK抑制剂以及利用PAK抑制剂治疗中枢神经系统疾病，如神经精神障碍的方法。